Literature DB >> 22031535

Interaction of low molecular weight hyaluronan with CD44 and toll-like receptors promotes the actin filament-associated protein 110-actin binding and MyD88-NFκB signaling leading to proinflammatory cytokine/chemokine production and breast tumor invasion.

Lilly Y W Bourguignon1, Gabriel Wong, Christine A Earle, Weiliang Xia.   

Abstract

Both high and low molecular weight hyaluronan (HMW-HA vs. LMW-HA) exist in various tissues and cells. In this study, we investigated LMW-HA-mediated CD44 interaction with Toll-like receptors (TLRs), the actin filament-associated protein (AFAP-110), and a myeloid differentiation factor (MyD88) in breast tumor cells (MDA-MB-231 cells). Our data indicate that LMW-HA (but not HMW-HA) preferentially stimulates a physical association between CD44 and TLRs followed by a concomitant recruitment of AFAP-110 and MyD88 into receptor-containing complexes in breast tumor cells. LMW-HA-activated AFAP-110 then binds to filamentous actin (F-actin) resulting in MyD88/nuclear factor-κB (NF-κB) nuclear translocation, NF-κB-specific transcription, and target gene [interleukine 1β and interleukine-8 (IL-1β and IL-8)] expression. These signaling events lead to proinflammatory cytokine/chemokine production in the breast tumor cells. AFAP-110-F-actin (activated by LMW-HA) also promotes tumor cell invasion. Downregulation of AFAP-110 or MyD88 by transfecting breast tumor cells with AFAP-110 siRNA or MyD88 siRNA, respectively not only blocks the ability of LMW-HA to stimulate AFAP-110-actin function, but also impairs MyD88-NF-κB nuclear translocation and NF-κB transcriptional activation. Consequently, both IL-1β/IL-8 production and tumor cell invasion are impaired. Taken together, these findings suggest that LMW-HA plays an important role in CD44-TLR-associated AFAP-110-actin interaction and MyD88-NF-κB signaling required for tumor cell behaviors, which may contribute to the progression of breast cancer.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22031535      PMCID: PMC3240717          DOI: 10.1002/cm.20544

Source DB:  PubMed          Journal:  Cytoskeleton (Hoboken)        ISSN: 1949-3592


  79 in total

Review 1.  Hyaluronan-cell interactions in cancer and vascular disease.

Authors:  Bryan P Toole; Thomas N Wight; Markku I Tammi
Journal:  J Biol Chem       Date:  2001-11-20       Impact factor: 5.157

Review 2.  Hyaluronan synthases.

Authors:  P H Weigel; V C Hascall; M Tammi
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

3.  Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression.

Authors:  Lilly Y W Bourguignon; Eli Gilad; Kori Rothman; Karine Peyrollier
Journal:  J Biol Chem       Date:  2005-01-17       Impact factor: 5.157

4.  CD44v10 interaction with Rho-kinase (ROK) activates inositol 1,4,5-triphosphate (IP3) receptor-mediated Ca2+ signaling during hyaluronan (HA)-induced endothelial cell migration.

Authors:  Patrick A Singleton; Lilly Y W Bourguignon
Journal:  Cell Motil Cytoskeleton       Date:  2002-12

Review 5.  CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression.

Authors:  L Y Bourguignon
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

6.  Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines.

Authors:  Jonna Frasor; Aisha E Weaver; Madhumita Pradhan; Kinnari Mehta
Journal:  Endocrinology       Date:  2008-08-14       Impact factor: 4.736

7.  Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan.

Authors:  Junji Uehori; Misako Matsumoto; Shoutaro Tsuji; Takashi Akazawa; Osamu Takeuchi; Shizuo Akira; Tsutomu Kawata; Ichiro Azuma; Kumao Toyoshima; Tsukasa Seya
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

8.  Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides.

Authors:  Mark G Slomiany; Lu Dai; Paul A Bomar; Thomas J Knackstedt; D Alex Kranc; Lauren Tolliver; Bernard L Maria; Bryan P Toole
Journal:  Cancer Res       Date:  2009-05-26       Impact factor: 12.701

9.  Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.

Authors:  Vummidi Giridhar Premkumar; Srinivasan Yuvaraj; Kothandaraman Vijayasarathy; Sitthu Govindaswamy Dinakaran Gangadaran; Panchanatham Sachdanandam
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-06       Impact factor: 4.080

10.  New CD44 splice variants associated with human breast cancers.

Authors:  N Iida; L Y Bourguignon
Journal:  J Cell Physiol       Date:  1995-01       Impact factor: 6.384

View more
  40 in total

Review 1.  Dissecting the role of hyaluronan synthases in the tumor microenvironment.

Authors:  Alberto Passi; Davide Vigetti; Simone Buraschi; Renato V Iozzo
Journal:  FEBS J       Date:  2019-04-22       Impact factor: 5.542

Review 2.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

3.  Actin Filament-Associated Protein 1-Like 1 Mediates Proliferation and Survival in Non-Small Cell Lung Cancer Cells.

Authors:  Meng Wang; Xingpeng Han; Wei Sun; Xin Li; Guohui Jing; Xun Zhang
Journal:  Med Sci Monit       Date:  2018-01-11

4.  Selective matrix (hyaluronan) interaction with CD44 and RhoGTPase signaling promotes keratinocyte functions and overcomes age-related epidermal dysfunction.

Authors:  Lilly Y W Bourguignon; Gabriel Wong; Weiliang Xia; Mao-Qiang Man; Walter M Holleran; Peter M Elias
Journal:  J Dermatol Sci       Date:  2013-06-05       Impact factor: 4.563

5.  Expression of versican V3 by arterial smooth muscle cells alters tumor growth factor β (TGFβ)-, epidermal growth factor (EGF)-, and nuclear factor κB (NFκB)-dependent signaling pathways, creating a microenvironment that resists monocyte adhesion.

Authors:  Inkyung Kang; Dong Won Yoon; Kathleen R Braun; Thomas N Wight
Journal:  J Biol Chem       Date:  2014-04-09       Impact factor: 5.157

Review 6.  Matrix hyaluronan-activated CD44 signaling promotes keratinocyte activities and improves abnormal epidermal functions.

Authors:  Lilly Y W Bourguignon
Journal:  Am J Pathol       Date:  2014-05-09       Impact factor: 4.307

7.  Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.

Authors:  Lilly Y W Bourguignon; Gabriel Wong; Christine Earle; Liqun Chen
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

8.  The hyaluronan receptor for endocytosis (HARE) activates NF-κB-mediated gene expression in response to 40-400-kDa, but not smaller or larger, hyaluronans.

Authors:  Madhu S Pandey; Bruce A Baggenstoss; Jennifer Washburn; Edward N Harris; Paul H Weigel
Journal:  J Biol Chem       Date:  2013-03-24       Impact factor: 5.157

Review 9.  Emerging roles for hyaluronidase in cancer metastasis and therapy.

Authors:  Caitlin O McAtee; Joseph J Barycki; Melanie A Simpson
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

10.  Hyaluronidase decreases neutrophils infiltration to the inflammatory site.

Authors:  Marcio Fronza; Cornélia Muhr; Denise Sayuri Calheiros da Silveira; Carlos Artério Sorgi; Stephen Fernandes de Paula Rodrigues; Sandra Helena Poliselli Farsky; Francisco Wanderley Garcia Paula-Silva; Irmgard Merfort; Lúcia Helena Faccioli
Journal:  Inflamm Res       Date:  2016-03-04       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.